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Abstract
Background: Serotonin is an important neurotransmitter with wide-ranging functions throughout
the central nervous system. There is strong evidence to suggest that regulation of serotonergic
gene expression might be related to genetic variability, and several studies have focused on
understanding the functional effects of specific polymorphisms within these genes on expression
levels. However, the combination of genotype together with gender and brain region could have
an overall effect on gene expression. In this study, we report expression patterns of five
serotonergic genes (TPH1, TPH2, 5-HT2A, 5-HT2C, 5-HTT) in seven different human post-mortem
brain regions (superior frontal gyrus, superior temporal gyrus, striatum, cerebellum, hippocampus,
midbrain and thalamus) using TaqMan™ real-time quantitative PCR. In addition, the effect of
genotype and gender on their expression levels was determined.
Results: The data revealed that mRNA from the five genes investigated was detected in all brain
regions and showed an overall significant difference in expression levels. Furthermore, the
expression of 5-HT2C, 5-HT2A and TPH2 was found to be significantly different between the various
brain regions. However, neither gender nor genotype showed significant effects on the expression
levels of any of the genes assayed. Interestingly, TPH1 and TPH2 were expressed in all brain regions
similarly except for within the striatum and cerebellum, where TPH1 was expressed at a significantly
higher level than TPH2.
Conclusion: The effect of brain region has a greater influence on serotonergic gene expression
than either genotype or gender. These data add to the growing body of evidence that effects of
functional polymorphisms on gene expression in vitro are not observed ex vivo, and provide
information that will aid in the design of expression studies of the serotonergic gene system within
human post-mortem brain.
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Background
Serotonin (5-HT) is an important neurotransmitter found
in neurons which project to various areas in the central
nervous system. Consequently it is associated with several
physiological mechanisms [1]. It mediates cellular effects
through several proteins that are involved with its neuro-
transmission, synthesis, metabolism and membrane re-
uptake [2,3]. Disturbances in brain serotonergic systems
result in a range of phenotypes such as depression, suicide
and anxiety disorders [3-5].
Many functional imaging and binding studies have dem-
onstrated that these disorders can, in part, be explained by
differential binding and/or function of components of the
serotonergic system such as receptors and enzymes. How-
ever, whether these observed differences correspond to
differences in gene expression is largely unknown. Regula-
tion of expression occurs via several different processes,
but most studies have focused on genetic variation as a
potential factor [6]. However, although many polymor-
phic variations have been demonstrated to elicit changes
in expression in vitro (studies in cell cultures), little infor-
mation on their role in ex vivo investigations using human
post-mortem brain tissue exists. Furthermore, despite
much attempt to determine a link between 5-HT pathway
gene polymorphisms and disease phenotype, few consist-
ent findings have been made including the promoter pol-
ymorphism in the 5-HTT gene and anxiety-related traits
[7,8]. Although there are many methodological and bio-
logical reasons for this, one explanation might be that dif-
ferential regulation could be elicited via additional factors
such as tissue type and gender as well as background
genetic variation.
Some of the most widely studied serotonergic genes
include tryptophan hydroxylase 1 and 2 (TPH1 and TPH2;
serotonin synthesis), serotonin receptors 2A and 2C (5-
HT2A  and 5-HT2C; post-synaptic receptors) and serot-
onin transporter (5-HTT, serotonin re-uptake). TPH is the
rate-limiting enzyme in the biosynthetic pathway of sero-
tonin and thus has a major function in regulating the ser-
otonergic system. Studies in mice have revealed the
existence of two isoforms of the gene termed as TPH1 and
TPH2, with rat and human homologues of the second iso-
form also cloned [9]. Although the discovery of TPH2 is
relatively recent, evidence has emerged in support of its
expression in human post-mortem brain. Firstly, TPH2
expression was observed in specific post-mortem brain
regions including cortex, thalamus, hippocampus, amy-
gdala and hypothalamus [10]. Secondly, differential
expression of TPH1 and TPH2 genes in various post-mor-
tem brain regions has been demonstrated, with TPH2
expression being significantly higher in raphe nuclei [10].
However, TPH1 expression was found to be significantly
higher than that of TPH2 in hypothalamus and amygdala.
The functional effects of genetic variation in TPH1 and
TPH2 genes have had little investigation. However, there
is evidence that in the TPH1 gene the TGT haplotype of 3
SNPs (T-1607C, G-1066A, T-346G) within the 5'regula-
tory region repressed transcriptional activity in human
cell lines [11]. Similarly, [12] have demonstrated that a
haplotype of 3 SNPs within the TPH2 promoter (G-703T,
T-473A, and A90G) also influenced transcription in rat
and human cell lines, the TTA haplotype resulting in
reduced gene expression.
5-HT2A and 5-HT2C receptors are both expressed post-
synaptically on serotonergic neurons. 5-HT2A receptors
are found mainly in the cortex and hippocampus [13,14]
whilst 5-HT2C receptors are found in greatest density in
the choroid plexus, although they are also located in other
brain regions such as the prefrontal cortex [15,16]. It has
been suggested that there is some similarity between the
neuronal distribution of 5-HT2A binding sites and 5-
HT2A  mRNA [14]. More recently, quantitative RT-PCR
has revealed more abundant 5-HT2A mRNA in the cortex
compared with the hippocampus in rat brain [17]. Inter-
estingly, 5-HT2A receptor density has been shown to be
under gender-specific influence, where men demon-
strated significantly higher binding capacity of receptors
than women [18].
There are a number of polymorphisms in the 5-HT2A
gene, some of which have been investigated in terms of
their effect on transcription, particularly the two highly-
linked SNPs T102C and A-1436G. Both the A and G alle-
les of the latter have significant basal promoter activity in
HeLa cells [19]. More recently, the transcriptional activity
of the G allele was found to be significantly lower than the
A allele when the more downstream of the two promoters
was included in the constructs and in the presence of an
enhancer region [20]. This effect was only observed in
endogenous 5-HT2A expressing cell-lines, suggesting the
presence of cell specific transcription factors is necessary
to elicit this functional effect. However, no differences
were found in allele-specific expression of the A-1436G
SNP in human post-mortem brain tissue [21].
Four variants within the promoter of the 5-HT2C gene
have been identified and their influence on gene expres-
sion investigated [22]. Two haplotypes each consisting of
a particular allele of an upstream GTn microsatellite (Z-6)
were found to increase expression of the gene relative to
the wild-type. Furthermore, this effect was not cell-spe-
cific, suggesting that it would be present in any tissue
expressing 5-HT2C.
5-HTT is responsible for re-uptake of serotonin at the pre-
synaptic neuron, and is the site of action of several selec-
tive serotonin reuptake inhibitors and tricyclic antidepres-BMC Neuroscience 2009, 10:50 http://www.biomedcentral.com/1471-2202/10/50
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sants. The gene is expressed widely in the brain with
highest expression detected in the dorsal raphe nuclei
[23]. One of the most documented variants within 5-HTT
is the serotonin transporter-linked polymorphic region
(5-HTTLPR), a repeat region which exists as two common
alleles, the short allele ('S') and long ('L'). There is evi-
dence that this polymorphic region has functional signif-
icance, where in human carcinoma cells and
lymphoblastoid cells, the L allele confers higher activity
than the S allele [24]. More recently, it has been shown
that the S and L alleles are themselves variable in that
SNPs occur within their repeating units [25]. Another
functional VNTR (variable number of tandem repeat)
within intron 2 of the 5-HTT gene has revealed differential
enhancer activities in the mouse embryo [26] and embry-
onic stem cells [27].
Here, we focused on first determining whether the mRNA
expression levels of TPH1, TPH2, 5-HT2A, 5-HT2C and 5-
HTT genes are affected by brain region, genotype or gen-
der. Real-time quantitative PCR (qPCR) was utilised to
determine the relative expression levels for these genes in
seven different human post-mortem brain regions. The
investigated polymorphisms are described above and are
located either within, or close to, the postulated promoter
region of the genes of interest suggesting a plausible func-
tional effect. Given the extensive literature concerning the
significance of TPH1 in disease aetiology, and the poten-
tial complication of the existence of its paralogue TPH2,
the second aim was to compare the levels of expression of
the two loci in the various brain regions.
Results
All genes assayed were expressed in all brain regions
tested, and these data are represented in Figure 1. Prelim-
inary analyses of the relative expression across all brain
regions (grouping individual 2-ΔCt  values) showed an
overall significant difference in the mRNA levels of the
five genes investigated (p < 0.001 F = 108.782). 5-HT2A
has an overall highest expression level, whereas 5-HTT
had the lowest expression level.
Effect of gender on gene expression
Gender did not have any significant effect on the overall
brain expression levels of the genes we assayed in this
sample (data combined for all seven brain regions). How-
ever, expression of most genes was generally higher in
males than in females (see Figure 2). Furthermore, there
were no significant gender differences on gene expression
levels within any of the brain regions we assayed (data not
shown).
Effect of brain region on gene expression
There were significant differences in expression levels of
three genes within different brain regions. These genes
included 5-HT2C (F = 19.297, p < 0.001), 5-HT2A (F =
17.952, p < 0.001) and TPH2 (F = 4.294, p = 0.001), and
are represented in the bar charts of Figure 3, 4 and 5,
respectively. The significant differences were consistently
described by lower expression in the cerebellum com-
pared to other brain regions as shown in Table 1.
Effect of genotype on gene expression
Genotype frequencies and results of ANOVA of the effects
of genotype on gene expression are shown in Table 2. As
5-HT2C is localised to the X-chromosome, we split the
sample by gender when assessing genotype effects. TPH1
did not show any variation in genotype (all samples were
"GG" after successful digestion, N = 11), and so no further
analyses could be performed for this gene. In general,
there were no significant effects of genotype on overall
brain expression of any of the genes that were analysed.
There appears to be a dose-dependant effect on expression
of the 5-HT2A gene by A-1438G genotype (mean 2-ΔCt ±
S.D.; AA genotype = 0.041 ± 0.048, AG genotype = 0.048
± 0.052, GG genotype = 0.054 ± 0.065; ANOVA F = 0.02,
p = 0.983). However, this failed to reach significance. Due
to the small numbers in the groups stratified by genotype
and allele frequency, further analysis of the effects of pol-
ymorphisms on within-brain region expression could not
be reliably performed.
Bar graph representing the expression (2-ΔCt) of five seroton- ergic genes before controlling for brain region, genotype or  gender Figure 1
Bar graph representing the expression (2-ΔCt) of five 
serotonergic genes before controlling for brain 
region, genotype or gender. All genes are expressed in 
the brain, 5-HTT showing the lowest expression and 5-HT2A 
the highest. Bars represent mean and error bars represent 
standard error of the mean (s.e.m).
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TPH1 vs. TPH2 expression
Overall expression of TPH1 is not significantly different to
that of TPH2 in this sample (t = 1.613, p = 0.101, mean 2-
ΔCt ± S.D.; TPH1 = 0.001 ± 0.0008, N = 68; TPH2 = 0.001
± 0.002, N = 63). However, when the data were further
analysed for each brain region the expression of TPH1 was
significantly higher than TPH2 in the striatum (t = 2.487,
p = 0.022) and cerebellum (t = 4.297, p < 0.001) (See Fig-
ure 6). There appear to be differences in the expression of
TPH1 and TPH2 in the hippocampus and thalamus but as
only a small number of data points were obtained for
these brain regions, no significant differences could be
determined. In addition, no significant differences exist
between the relative expression of TPH1 and TPH2 when
stratified by gender (data not shown).
As the possible presence of Alzheimer's disease at death
was recorded for 8 individuals, we tested for its possible
impact on transcription. However, there was no signifi-
cant influence of this phenotype on the difference in gene
expression levels in all brain regions tested (TPH1, t =
1.33, d.f. = 13, p = 0.21, TPH2, t = 0.62, d.f. = 13, p = 0.55;
5-HT2A, t = 2.17, d.f. = 8, p = 0.06; 5-HT2C, t = 0.85, d.f.
= 13, p = 0.41; 5-HTT, t = 2.04, d.f. = 13, p = 0.06).
Discussion
This is the first investigation, to our knowledge, that com-
pares the expression patterns of different serotonergic
genes in various human post-mortem brain regions. The
results suggest that all five serotonergic genes are
expressed in human post-mortem brain tissue and signif-
icant overall differences in expression of 5-HT2A, 5-HT2C
and  TPH2  were observed between the various brain
regions analysed. This is in agreement with previous find-
ings that show variation in receptor densities between
brain regions [28-30], and suggests that these differences
in protein levels might be determined by transcriptional
regulation to some degree. Differences in abundance of
these various serotonergic transcripts throughout the
brain suggest differential gene regulation between specific
brain regions. Therefore, it is important to take into con-
sideration the brain region from which the mRNA is
derived when performing comparative post-mortem brain
expression studies.
Perhaps most surprisingly, there appeared to be little
effect of genetic variation on the overall brain expression
of the genes we analysed. Although it has been suggested
that expression of all five genes is regulated by promoter
polymorphisms  in vitro [11,12,20,22,31], we did not
observe the same effect ex vivo. Similar results have been
Bar graph representing the effect of gender on expression (2- ΔCt) of the five genes in all brain regions Figure 2
Bar graph representing the effect of gender on 
expression (2-ΔCt) of the five genes in all brain 
regions. Males (grey bars) and females (white bars) repre-
sent the mean and error bars representing s.e.m. No signifi-
cant differences in expression are observed. 
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Bar graph describing the expression (2-ΔCt) of 5-HT2C in vari- ous brain regions Figure 3
Bar graph describing the expression (2-ΔCt) of 5-HT2C 
in various brain regions. There are significant differences 
in expression (denoted by ** [p < 0.001]) across the brain 
regions, mainly due to lower expression of genes in the cere-
bellum. The symbol * represents a significant difference P = 
0.003 between 5-HT2C expression in striatum and STG brain 
regions (see Table 1). Bars represent the mean and error 
bars represent s.e.m. The groups representing expression in 
the thalamus have N = 2.
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observed in previous expression studies in human post-
mortem brain. For example, differences in 5-HT2A expres-
sion were not observed between the 'A' and 'G' allele of
the 5-HT2A A-1438G SNP [21], and allelic ratios of 5-HTT
mRNA are not correlated to 5-HTTLPR  genotype in
human pons [32] or brainstem [33]. Whilst our data are
in agreement with these findings, interpretation should be
with some caution due the small sample size for each gen-
otype group. This limits our ability to determine any brain
region-specific effects of genetic variation on gene expres-
sion. Therefore these findings will need to be confirmed
by using a larger sample-size in future studies. In addition,
other potential confounders that were not measured
could have an effect. For example, there has been a report
of 5-HT2A  imprinting in human fibroblasts and brain
[34], although other independent studies found no fur-
ther evidence for this phenomenon [21,35]. Overall, the
data described here suggest that the postulated functional
polymorphisms do not affect gene expression and this
may reflect the complexity of gene regulation ex vivo.
No effects of gender on expression levels were observed
for any of the genes within this sample. Interestingly, little
data exist to date regarding the effect of gender on the
expression of human serotonergic genes. However, there
is evidence to suggest that gender-specific hormones
might exert some regulatory effect on expression in
rodents and primates. In Rhesus macaques, administra-
tion of oestrogen and progesterone resulted in a decrease
in expression of 5-HT2C in the hypothalamus [36], whilst
treatment of rats with oestradiol lead to a decrease in 5-
HT2C expression in the hippocampus [37]. Subsequently,
the expression of both TPH1 and TPH2 was shown to
increase in the dorsal raphe nuclei of both mice [38] and
macaques [39] following oestradiol administration. In
addition, both testosterone and oestrogen were capable of
increasing the number of 5-HTT cells in castrated male
rats [40]. A limitation of the observations of our studies
regarding the situation in humans is that the tissue donors
were elderly, and reports of the normal levels of sex hor-
mones within this age group are conflicting [41,42].
Finally, the results observed here reveal that TPH1 expres-
sion is detected in all investigated brain regions at a com-
parable or higher level than that of TPH2. These data
confirm recent findings [10], where TPH1 expression was
observed in human brain, and that expression of TPH1
was significantly higher than that of TPH2 in some of the
Bar graph describing the expression (2-ΔCt) of 5-HT2A in vari- ous brain regions Figure 4
Bar graph describing the expression (2-ΔCt) of 5-HT2A 
in various brain regions. There are significant differences 
in expression (denoted by ** [p < 0.001] and * [p ≤ 0.04]) 
across the brain regions, mainly due to lower expression of 
genes in the cerebellum (see Table 1). Bars represent the 
mean and error bars represent s.e.m.
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Bar graph describing the expression (2-ΔCt) of TPH2 in vari- ous brain regions Figure 5
Bar graph describing the expression (2-ΔCt) of TPH2 in 
various brain regions. There are significant differences in 
expression (denoted by ** [p = 0.001] and * [p = 0.011]) 
across the brain regions, mainly due to lower expression of 
genes in the cerebellum (see Table 1). Bars represent the 
mean and error bars represent s.e.m. The groups represent-
ing expression in the thalamus have N = 2.
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brain regions we also examined (frontal cortex, thalamus,
hippocampus, hypothalamus and amygdala). Our data
show that TPH1 expression is higher than that of TPH2 in
the striatum and cerebellum, but not the hippocampus.
This inconsistency could be related to variables we could
not measure, or factors such as the differing mean ages of
samples analysed in this study and that by Zill and col-
leagues [10], since there is evidence that increasing age
enlarges the heterogeneity of gene expression contributing
to greater inter-individual variability in expression [43].
Additionally, the discrepancy in our results with that of
Zill and colleagues could be due to the existence of tran-
scriptional variants for TPH2 mRNA in humans. Recent
evidence in rats has revealed that TPH2 has two transcrip-
tional variants one of which is expressed at a very low level
[44]. The potential of TPH2 mRNA splice variants has not
been demonstrated in humans to date and warrants future
investigation.
The original discovery of the novel TPH2 isoform led to
the hypothesis that it was TPH2 not TPH1 that was the rel-
evant 5-HT catabolic gene in brain tissue based on its
much higher expression level (150 times more) in the
brain stem of mice [9]. This region contains raphe nuclei
which are rich in serotonergic neurons and our results dif-
fer from these previous studies as we focused on several
other brain areas which did not include the brain stem.
Prior to discovery of TPH2, brain regional differences in
TPH densities were traditionally explained by differences
in translational efficiencies of splice variants [45]. How-
ever, this might now be explained by region specific
expression of the two TPH isoforms. Our data support this
hypothesis as TPH1 is expressed in all brain regions, and
that there are brain region specific differences in expres-
sion of TPH1 and TPH2. Although emerging data suggest
that TPH1 is not sufficient to drive serotonergic metabo-
lism in the brain, it is expressed, albeit at differing levels,
and as such does not preclude its role in the regulation of
serotonergic functioning. Furthermore, TPH1 in the pin-
eal gland is essential in the synthesis of melatonin, a
mechanism by which it can, in turn, influence serotoner-
gic functioning and behaviour [46].
Although we attempted to control for factors that could
have an effect on results described here, there are other
confounding issues to consider. Firstly, the sample size is
small, which might lead to bias in group comparisons.
Furthermore, specific conditions at the time of death and
post-mortem (e.g. Post mortem interval, PMI) signifi-
cantly affect RNA integrity and abundance [47-50]. How-
ever, these studies show that post-mortem intervals of 48
hours do not affect expression levels. The PMI of the post-
mortem samples utilised in this study were 38.67 ± 16.62
hours (mean ± S.D.) and within the limit so that gene
expression levels would not be affected.
Real-time qPCR ('TaqMan') was utilised to quantify gene
expression since it is a highly reproducible and sensitive
technique [51,52]. The relative quantification method of
analysis was employed which compares the expression
level of a target gene to the expression of an endogenous
control gene. This high-throughput method has been suc-
Table 1: Results of comparisons of gene expression levels for those genes showing differences between brain regions
Gene Brain region 1 Brain region 2 Mean Difference
(1–2)
Std. Error Bonferroni-corrected
p value
95% Confidence Intervals
5-HT2C CEREBELLUM SFG -0.779 0.176 0.001 -1.334 -0.223
STG -1.041 0.179 <0.001 -1.606 -0.476
STRIATUM -1.748 0.173 <0.001 -2.295 -1.201
MIDBRAIN -1.180 0.210 <0.001 -1.843 -0.518
THALAMUS -1.835 0.358 <0.001 -2.965 -0.705
HIPPOCAMPUS -1.338 0.247 <0.001 -2.117 -0.559
STRIATUM SFG 0.969 0.170 <0.001 0.432 1.506
STG 0.706 0.173 0.003 0.159 1.253
5-HT2A CEREBELLUM SFG -1.430 0.164 <0.001 -1.948 -0.911
STG -1.427 0.164 <0.001 -1.946 -0.909
MIDBRAIN -0.706 0.196 0.012 -1.324 -0.088
STRIATUM -0.934 0.170 <0.001 -1.471 -0.397
HIPPOCAMPUS -1.267 0.230 <0.001 -1.994 -0.541
SFG MIDBRAIN 0.724 0.193 0.008 0.113 1.335
THALAMUS 0.905 0.279 0.039 0.023 1.788
STG MIDBRAIN 0.721 0.193 0.008 0.111 1.332
THALAMUS 0.903 0.279 0.040 0.021 1.785
TPH2 CEREBELLUM SFG -0.746 0.203 0.011 -1.392 -0.101
HIPPOCAMPUS -1.205 0.277 0.001 -2.087 -0.323
Mean differences were calculated where relative expression values of brain region 2 were subtracted from the value of brain region 1. The 
significance levels and 95% confidence levels are listed for comparisons that show significant differences only.BMC Neuroscience 2009, 10:50 http://www.biomedcentral.com/1471-2202/10/50
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cessfully used in previous gene expression studies with
post-mortem human brain and biopsies [53,54]. How-
ever, there are some caveats to be made regarding choice
of suitable endogenous control gene, especially in regards
to expression stability. In this study, SDHA, UBC and
GAPDH  housekeeping genes were used as endogenous
controls based on previous data which showed these
genes to be most stably expressed in human neuroblast-
oma cells [55]. The results did not reveal any significant
differences between relative expression values when nor-
malised to each of the endogenous control genes sepa-
rately (data not shown), thus differential expression of
control gene is unlikely to be a confounding factor.
Conclusion
This investigation has demonstrated the differential
expression of 5-HT genes in several human post-mortem
brain tissue regions using real-time qPCR. These data pro-
vide additional information that will be relevant for
appropriate sample selection when performing gene
expression studies involving human brain. Both gender
and transcriptionally-relevant polymorphisms appear to
have little influence on ex vivo expression within this sam-
ple suggesting that complex interactions present in
human brain tissue might eclipse the genetic effects that
are consistently observed in vitro. These results, taken
together with those from alternative approaches such as
animal models, in vitro and neuroimaging studies, will
contribute to the understanding of these interactions and
inform researchers of the mechanisms that regulate sero-
tonergic gene expression in human brain.
Methods
The sample consisted of brain tissue collected from 15
individuals post-mortem (9 Male, 6 female) provided by
the Maudsley Brain Bank (Department of Neuropathol-
ogy, Institute of Psychiatry, London, UK) and stored at -
70°C prior to use. These individuals were normal (N = 7)
adults and Alzheimer's patients (N = 8) with agonal states
of either cardiac failure, bronchopneumonia, myocardial
infarction, hypertension, coronary occlusion, carcinoma
of left kidney, ischaemic heart disease, pulmonary embo-
lus. Mean age at death for the sample was 78.0 ± 7.4 years
(mean ± s.d.), and mean post-mortem delay was 38.7 ±
16.6 (mean ± s.d.) hours. No significant differences were
observed between males and females with regard to either
age at death (males: 77.6 ± 7.0 years (mean ± s.d.);
females: 79.2 ± 8.6 years (mean ± s.d.) t = -0.381, p =
0.712) or post-mortem delay (males 38.2 ± 14.1 hrs
(mean ± s.d.); females 39.3 ± 21.3 hrs (mean ± s.d.); t = -
Table 2: Results of expression analyses by genotype
H-W test  ANOVA
Gene/Marker Genotype Genotype
 Frequency
(N)
Allele Allele
Frequency
(N)
 χ2 value PFP
5-HT2A AA 0.29 (4) A 0.46 (13) 0.57 0.75 0.02 0.983
A-1438G AG 0.36 (5) G 0.54 (15)
GG 0.36 (5)
N = 14
5-HT2C
promoter microsatellite M Z 0.67 (4) 0.02 0.98
Z-6 0.33 (2)
F Z-6/Z-6 0.14 (1) Z-6 0.36 (5) 0.84 0.89 0.14 0.933
Z-6/Z 0.29 (2) Z 0.57 (8)
Z-6/Z+2 0.14 (1) Z+2 0.07 (1)
Z/Z 0.43 (3)
N = 13
TPH2 GG 0.69 (9) G 0.85 (22) 0.94 0.33 1.47 0.23
G-703T GT 0.31 (4) T 0.15 (4)
N = 13
5-HTT SS 0.07 (1) S 0.39 (11) 0.43 0.81 0.10 0.91
5-HTTLPR SL 0.64 (9) L 0.61 (17)
LL 0.29 (4)
N = 14
5-HTT 10/10 0.09 (1) 10 0.23 (5) 0.72 0.70 0.02 0.98
Intron 2 VNTR 10/12 0.27 (3) 12 0.77 (17)
12/12 0.64 (7)
N = 11
Genotype frequencies, allele frequencies, results of H-W (Hardy-Weinberg) tests and ANOVA comparisons of gene expression levels (log(10) 2-ΔCt) 
values for the polymorphic variants are shown. Genotypes of the 5-HT2C marker are split by gender (Males = M; Females = F) since the males are 
hemizygotic.BMC Neuroscience 2009, 10:50 http://www.biomedcentral.com/1471-2202/10/50
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0.112, p = 0.913). From each individual, samples from up
to 7 different brain regions were collected and included
the following: superior frontal gyrus (SFG; N = 15), supe-
rior temporal gyrus (STG; N = 15), hippocampus (N = 7),
cerebellum (N = 15), midbrain (N = 9), thalamus (N = 3)
and striatum (N = 14). The Ethical Committee (Research)
at the Institute of Psychiatry considered and approved this
experimental project and the reference study number is
167/00.
Nucleic acid preparation
Brain tissue was stored at -80°C prior to total RNA and
DNA extraction using TRI reagent (Sigma, UK) following
the manufacturer's instructions. Total RNA was DNase I
treated using Qiagen RNeasy kit (Qiagen, UK) and DNase
I (Qiagen, UK) following manufacturer's recommenda-
tions. cDNA was generated from total RNA using the Taq-
Man RT-PCR kit (Applied Biosystems, UK). Briefly, 1 μg of
total RNA was reverse transcribed with 5.5 mM of MgCl,
500 μM of each dNTP, 2.5 μM random hexamers and 0.4
U/μL RNase inhibitor in a total volume of 20 μl. Samples
were incubated at 25°C for 10 minutes, followed by 48°C
for 30 minutes and then denatured at 95°C for 5 minutes
in a thermocycler.
Relative quantitative real-time PCR using 'TaqMan'
Primers and probes for each gene were obtained via
'Assays-on-demand' (Applied Biosystems, UK). All probes
were tested for equal reaction efficiencies prior to use by
making a serial dilution of a single cDNA sample (range
1–103 dilution). All probes showed an amplification effi-
ciencies in the accepted range (0.98 – 1.02). Assay ID
numbers are listed in Table 3. All probes are designed to
span adjacent exons to minimise effects of any residual
DNA contamination.
TaqMan reactions were performed using 0.5 μl Assays-on-
demand primer/probe, 5 μl 2× TaqMan mastermix
(Applied Biosystems, UK), 0.5 μl cDNA and appropriate
volume of primer and probe in a total volume of 10 μl.
Concurrently, three housekeeping endogenous controls
were assayed for each individual sample for normalisa-
tion purposes (Succinate Deydrogenase (SDHA), Ubiqui-
tin C (UBC) and Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) [55]). Each experiment was per-
formed in triplicate. The TaqMan reaction was carried out
using an ABI7900HT sequence detection system set up in
absolute quantification mode. Cycling conditions were
one cycle of 95°C at 10 minutes, followed by 40 cycles of
95°C at 15 sec and 60°C for 1 min. On completion of
PCR, Ct values were generated using SDS 2.1. software.
Genotyping
The following polymorphisms were genotyped: 5-
HTTLPR and intron 2 VNTR (5-HTT), T-346G (TPH1), G-
703T (TPH2), A-1438G (5-HT2A), GTn microsatellite (5-
HT2C). Details of these markers, PCR reaction conditions
and detection methods are given in Table 3. PCR reactions
consisted of 2.5 μl × 10 PCR reaction buffer IV (Abgene,
UK), 200 mM dNTPS (Abgene, UK), 1 unit Taq polymer-
ase (Promega, UK), 10 pmol each primer, appropriate
concentration of MgCl2 and 25 ng template DNA up to 25
μl. Cycling conditions consisted of initial denaturation at
94°C for 4 minutes followed by 30 cycles of 95°C for 1
minute, appropriate annealing temperature for 1 minute
and 72°C for 1 minute, followed by a final elongation
step at 72°C for 4 minutes. PCR reactions were carried out
using an MJ research tetrad thermal cycler (MJ research,
UK).
Enzyme digests were carried out using MspI (Promega,
UK) or MslI (NEB, USA) following manufacturer's instruc-
tions. Digested samples were subjected to agarose gel elec-
trophoresis using a 2% agarose gel (Abgene, UK) and
visualised using UV transillumination (UVP, UK). Those
assays requiring capillary gel electrophoresis were ana-
lysed using an ABI3100 (Applied Biosystems) set up in
Bar graph of mean expression (2-ΔCt) of TPH1 (grey bars)  versus TPH2 (white bars) and error bars representing s.e.m Figure 6
Bar graph of mean expression (2-ΔCt) of TPH1 (grey 
bars) versus TPH2 (white bars) and error bars repre-
senting s.e.m. Both genes are expressed in all brain regions, 
and TPH1 expression is significantly higher than TPH2 in both 
the striatum (t = 2.487, p = 0.022, denoted by *) and cerebel-
lum (t = 4.297, p < 0.001, denoted by **). The groups repre-
senting TPH2 expression in the hippocampus and thalamus 
have a much larger variance than that of TPH1, probably due 
to the smaller number of individuals in these groups (hippoc-
ampus N = 5, thalamus N = 2).
* **
0.010
2
-
ǻ
C
t
0.005
0.000
STG Cerebellum
SFG Midbrain
Striatum
Thalamus
Hippocampus
Brain RegionBMC Neuroscience 2009, 10:50 http://www.biomedcentral.com/1471-2202/10/50
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genotyping mode. 1 μl PCR product was prepared in 12 μl
HI-DI formamide and 0.4 μl GSRox size standard
(Applied Biosystems, UK), denatured at 95°C for 10 min-
utes and snap cooled on ice. Data were analysed using
Genotyper V3.6 software (Applied Biosystems, UK).
Statistical analyses
Mean triplicate Ct values for each sample were calculated,
and outliers within the triplicates removed using Grubb's
method. Briefly, if the obtained Z value (the difference
between the investigated Ct and the mean Ct divided by
the SD) exceeded the critical value 1.15, the sample was
considered an outlier and removed from further analysis.
The mean Ct values were used to calculate relative expres-
sion using the ΔCt method [56] where normalisation
using multiple reference genes was employed. The nor-
malisation index was calculated as the arithmetic mean Ct
of the three housekeeping genes (GAPDH, UBC, SDHA).
The ΔCt was then calculated by subtracting the normalisa-
tion index from the mean target Ct, and then the relative
expression is calculated using the formula 2-ΔCt. Relative
expression values (2-ΔCt) were log-transformed prior to
analysis since these values are not normally distributed
[57]. Student's t test or ANOVA with post-hoc Bonferroni
correction and Games-Howell test were performed.
The statistical package for social scientists (SPSS, USA)
was employed in all analyses, and grouping variables were
gender, genotype and brain region.
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